Realm Therapeutics PLC (LON:RLM)‘s stock had its “corporate” rating reiterated by investment analysts at N+1 Singer in a note issued to investors on Monday.

Realm Therapeutics PLC (LON RLM) opened at 29.50 on Monday. The firm has a 50-day moving average of GBX 30.32 and a 200-day moving average of GBX 31.45. Realm Therapeutics PLC has a 52-week low of GBX 19.50 and a 52-week high of GBX 37.00. The stock’s market capitalization is GBX 14.80 million.

ILLEGAL ACTIVITY NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at

About Realm Therapeutics PLC

Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology.

Receive News & Stock Ratings for Realm Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Realm Therapeutics PLC and related stocks with our FREE daily email newsletter.